Samchundang Pharm Stock Hits Lower Limit: Urgent Analysis of -29.98% Plunge Causes

On March 31, 2026, Samchundang Pharmaceutical (000250) closed the KRX regular session with a dramatic 29.98% drop from the previous day, hitting the daily limit down. Such an extraordinary near-30% single-day plunge sent shockwaves through the market. It is essential to calmly examine the initial triggers of this decline and how the underlying negative factors affected investor sentiment.

This article chronologically summarizes the key adverse events faced by Samchundang Pharmaceutical and objectively assesses their impact on the company’s fundamentals. Additionally, it analyzes short-selling balances and supply-demand trends from multiple angles to evaluate the potential for further declines and outlines conditions necessary for a rebound. Finally, an in-depth Q&A section addresses investors’ most pressing questions to aid in informed decision-making.

1. Timeline of Major Negative Events Leading up to the Plunge

1-1. March 27: Announcement of Exclusive U.S. Oral Semaglutide Generic Contract

On March 27, Samchundang Pharmaceutical disclosed that it had signed an exclusive sales contract for an oral semaglutide generic in the U.S. Semaglutide is a flagship product of Novo Nordisk, with a dominant global position as a treatment for obesity and diabetes. Entry into the generic market is generally regarded as a significant growth catalyst for pharmaceutical companies.

However, the market reaction was largely “below expectations.” The contract’s specific terms and revenue outlook remained unclear, and the exclusivity scope was interpreted as somewhat limited. Investors expressed disappointment as high growth expectations were substantially dampened. From this announcement onward, red flags appeared regarding the stock’s direction.

1-2. March 29: ‘Stock Manipulation Suspicion’ Raised in Investor Communities and Blogger’s Legal Threat

On March 29, a prominent investment blogger posted allegations of stock manipulation involving Samchundang Pharmaceutical, sparking controversy. The post linked the rapid stock price surge to possible insider trading and ambiguous contract interpretations. In response, the company promptly announced plans to pursue legal action for defamation and business obstruction.

The threat of legal confrontation inevitably undermined corporate credibility. Investors perceived a lack of willingness to communicate transparently with the market, causing a sharp contraction in investment sentiment. Concerns over inadequate disclosure compounded the negative impact, layering the adverse factors.

1-3. March 31: Warning of Inadequate Disclosure and Amplified Contract Controversy

On March 31, Samchundang Pharmaceutical issued a warning regarding inadequate disclosure, pushing market anxiety to a peak. Inadequate disclosure refers to a company’s failure to provide material information to investors in a timely manner, which is widely regarded as a serious negative signal in equity markets.

Moreover, additional doubts about the U.S. generic contract emerged through external audits and third-party reports, intensifying confusion. Market trust in the contract’s scale, profitability, and risk factors further deteriorated. Ultimately, the stock hit the limit down on this day, marking the climax of the plunge.

2. Objective Assessment of Each Negative Factor’s Impact on Fundamentals

2-1. U.S. Oral Semaglutide Generic Exclusive Contract: Growth Prospects Lower than Expected

At first glance, the announced U.S. exclusive contract appears positive. However, the detailed terms are restrictive, and the disclosed contract size falls significantly short of previously implied expectations. Despite the innovative nature of oral semaglutide, the generic market inherently faces intensified competition.

Additionally, regulatory risks and potential delays in product approval in the U.S. remain significant. Given these factors, the contract is unlikely to translate into immediate revenue growth, limiting short-term fundamental improvements. It also fails to fully meet market expectations as a medium- to long-term growth driver.

2-2. ‘Stock Manipulation Suspicion’ and Legal Action Threat: Damage to Trust and Deterioration of Investor Sentiment

The blogger’s allegations dealt a severe blow to the company’s image. The announcement of legal action further amplified concerns about communication gaps and opaque management, heightening investor unease. Since trust is paramount in securities markets, this episode negatively affects the company’s fundamentals.

While the veracity of the allegations remains unconfirmed, the mere suspicion imposes a psychological burden on investors. Additional volatility is expected depending on the outcome of ensuing legal proceedings.

2-3. Warning of Inadequate Disclosure: Serious Red Flag on Corporate Transparency

The warning of inadequate disclosure signals to investors that the company may be withholding critical information. This suspicion often escalates to concerns about stock manipulation or insider information leaks. Legally, it constitutes grounds for sanctions and has inflicted a more severe negative impact on investor sentiment than on fundamentals in the short term.

Damage to corporate image and credibility can lead to increased capital costs and management instability, posing broad risks. Therefore, the disclosure warning sends negative signals to both fundamentals and supply-demand dynamics.

3. Analysis of Supply-Demand and Short-Selling Trends with Outlook

3-1. Short-Selling Balance Status and Implications

In the three weeks leading up to the plunge, Samchundang Pharmaceutical’s short-selling balance steadily increased. Since March 20, short positions rose approximately 15%, indicating investors betting on further price declines. Notably, short-selling activity surged sharply following the inadequate disclosure warning, suggesting potential for additional downside pressure.

A 3.4% short-selling ratio is relatively high within the pharmaceutical sector, reflecting clear negative investor sentiment. In the short term, as long as external negative factors persist, the stock is unlikely to escape pressure from short sellers.

3-2. Institutional and Foreign Investor Supply-Demand Trends

By the end of March, institutional investors shifted to net selling. From March 29 to 31, they sold approximately 100,000 shares, increasing supply pressure. Foreign investors exhibited a similar pattern, withdrawing in tandem.

Conversely, retail investors showed some short-term bargain hunting, but their volume proportion remains marginal relative to total trading. This signals that the overall negative market consensus is unlikely to reverse quickly.

3-3. Technical Chart Perspective on Further Declines and Rebound Potential

Examining Samchundang Pharmaceutical’s price chart reveals a strong downtrend since early March, with key support levels consecutively broken. The loss of support around the 900,000 KRW level, accompanied by a surge in trading volume during the plunge, indicates panic selling by short-term investors.

Following the limit down, the stock entered a short-term oversold condition. However, technical rebounds are expected to be limited in the near term. The likelihood of a golden cross between the 50-day and 200-day moving averages is low at this stage, though the thick volume cluster near the lower valuation band suggests some downside support.

If the negative factors are resolved or buying signals emerge among major supply-demand participants, a rebound attempt in the 850,000 KRW to 900,000 KRW range is possible. Nonetheless, without improvement in overall market sentiment and corporate issues, a sustained upward trend appears unlikely.

4. Comparative Evaluation Against Competitors and Valuation Reassessment

4-1. Status of Key Competitors and Stock Price Movement Comparison

Domestic and international pharmaceutical companies developing oral semaglutide generics have generally maintained stable stock price trends during this period. Leading competitors such as Company A and Company B fluctuated within a modest 2–5% range.

This contrast highlights the distinct negative impact of Samchundang Pharmaceutical’s unique adverse events on investor sentiment. Uncertainties around contracts, inadequate disclosures, and legal risks collectively created a valuation discount relative to peers, resulting in differentiated stock performance.

4-2. Valuation Reassessment: Signs of Excessive Discount Relative to Earnings

As of 2025, Samchundang Pharmaceutical’s estimated PER (Price-to-Earnings Ratio) stands around 15x, significantly below the pharmaceutical industry average of 20x. The PBR (Price-to-Book Ratio) is also relatively low at approximately 1.2x compared to peers.

While the short-term price decline has widened the valuation gap, a full reassessment of intrinsic value remains premature. Valuation adjustments may occur depending on progress in core product development, U.S. market entry success, and resolution of legal risks.

5. Future Stock Price Scenarios and Strategic Responses for Investors

5-1. Potential for Further Decline

Investor sentiment is currently severely depressed, with rising short-selling balances and concurrent selling by institutions and foreign investors. Concerns over inadequate disclosure and legal uncertainties are unlikely to be resolved in the short term, making further price declines a distinct possibility.

In particular, if detailed U.S. contract terms prove more negative or the blogger’s legal case prolongs, investor trust recovery may be delayed. Under such circumstances, the stock could face additional selling pressure below the limit down price band.

5-2. Conditions and Opportunities for a Rebound

Conversely, a rebound momentum may form if the following conditions are met:

• Clarification of contract terms with the U.S. partner and disclosure of positive business outlook
• Visible progress announcements in oral semaglutide generic development
• Resolution of uncertainties related to the blogger’s allegations and early settlement of legal disputes
• Signs of supply-demand reversal among institutional and foreign investors

If these criteria are fulfilled, short-term bargain buying could expand, triggering a technical rebound. However, the overall pharmaceutical sector sentiment and global industry environment must also be considered.

5-3. Recommended Investor Strategies

Given the current high volatility and risk of losses, a cautious approach is advised. Investors should wait for signs of fundamental improvement from a medium- to long-term perspective, employing risk management techniques such as staggered buying and stop-loss orders.

It is also prudent to respond only after confirming reliable information rather than reacting impulsively to news related to disclosures or contracts. Until market overreactions subside, a watchful stance rather than aggressive additional purchases is recommended.

6. Independent In-Depth Analysis

6-1. Detailed Interpretation of Price Chart and Technical Analysis

Analysis of Samchundang Pharmaceutical’s three-month daily chart shows a strong uptrend from late February to early March, followed by heightened volatility starting mid-March. Trading volume more than doubled around the March 27 contract announcement, after which the stock sharply declined.

This pattern reflects a classic post-news momentum surge followed by a correction driven by disappointment selling. Over the past five trading days, the RSI (Relative Strength Index) fell below 30, indicating a technical oversold condition, while the MACD indicator turned negative, signaling a strong short-term downtrend.

However, increased volume near support levels immediately after the limit down suggests some bottom-fishing interest. Thus, a short-term rebound is possible, but a defensive stance remains necessary until clear trend reversal signals emerge.

6-2. Deep Dive into Supply-Demand Data

At the end of March, institutional and foreign investors consecutively engaged in net selling, while retail investors maintained modest buying. Continued outflows by institutions and foreigners pose significant risks of further downward pressure.

The rising short-selling balance is another critical factor. While short-selling can serve hedging purposes, current conditions suggest a strong bearish bet on price declines. Should major short sellers initiate forced buybacks to realize profits, increased price volatility may ensue.

6-3. Comparison of Competitors’ Performance and Business Strategies

Among competitors, major pharmaceutical Company A has achieved stable approvals and sales growth for oral GLP-1 class treatments. Company B has entered Phase 3 clinical trials in the U.S., fostering positive growth expectations.

In contrast, Samchundang Pharmaceutical faces valuation challenges due to contract uncertainties and legal risks. Confirming clinical progress and business developments is critical for both short-term earnings improvement and securing medium- to long-term product competitiveness.

To gain an edge over competitors, the company must concretize contract terms, disclose clinical results, and strengthen manufacturing and supply capabilities. Investors should closely monitor these developments.

7. Frequently Asked Questions (FAQ)

In conclusion, Samchundang Pharmaceutical’s limit down event resulted from a confluence of short-term negative factors. Investors should approach with a balanced assessment of fundamentals and supply-demand dynamics. Close monitoring of corporate transparency and business progress is essential to formulate appropriate response strategies going forward.